Optimistic Buy Rating on uniQure Amidst Progress in Huntington’s Disease Program and AMT-130 Developments

uniQure (QURE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 9. Analyst Joseph Schwartz from Leerink Partners maintained a Buy rating on the stock and has a $48.00 price target.

Joseph Schwartz has given his Buy rating due to a combination of factors including uniQure’s progress in their Huntington’s disease program and the potential of their lead therapy, AMT-130. The company has been making significant strides in its regulatory pathway, having established an accelerated approval process with the FDA. Recent meetings with the FDA have focused on critical aspects such as CMC requirements and statistical analysis plans, indicating a clear path forward for their BLA submission.
Furthermore, Schwartz acknowledges the volatility in QURE’s stock due to regulatory developments but remains optimistic about the potential upside. The upcoming data presentations from the ongoing Phase 1/2 studies of AMT-130, which include long-term follow-up data, are expected to provide further insights into the therapy’s efficacy and safety. These developments, alongside a well-tolerated immunosuppression regimen in their study, contribute to the positive outlook on uniQure’s stock.

Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year.